Title: Joint analysis reveals shared autoimmune disease associations 1

- and identifies common mechanisms 2
- 3

4 Short title

- 5 Joint analysis of autoimmune diseases
- 6

7 One sentence summary:

8 Genetic mapping in autoimmune diseases increases genetic mapping resolution and reveals 9 shared mechanisms

10

11 Authors:

- 12 Matthew R Lincoln¹, Noah Connally¹, Pierre-Paul Axisa¹, Christiane Gasperi¹, Mitja Mitrovic¹,
- David van Heel², Cisca Wijmenga³, Sebo Withoff³, Iris H Jonkers³, Leonid Padyukov⁴, 13
- 14 International Multiple Sclerosis Genetics Consortium, Stephen S Rich^{5,6}, Robert R Graham^{7,8}, Patrick M Gaffney⁹, Carl D Langefeld^{10,11}, David A Hafler¹, Sung Chun^{12,13}, Shamil R Sunayev^{12,13},
- 15 Chris Cotsapas^{1,14}
- 16
- 17

18 Affiliations:

- ¹Department of Neurology, Yale School of Medicine, New Haven, CT 19
- 20 ²Blizard Institute, Queen Mary University of London, London, UK
- 21 ³Department of Genetics, University Medical Center Groningen, University of Groningen,
- 22 Groningen, The Netherlands
- 23 ⁴Division of Rheumatology, Department of Medicine, Karolinska Institutet and Karolinska
- 24 University Hospital, Stockholm, Sweden
- 25 ⁵Center for Public Health Genomics. University of Virginia, Charlottesville, VA
- ⁶Department of Public Health Sciences, University of Virginia, Charlottesville, VA 26
- ⁷Maze Therapeutics, South San Francisco, CA 27
- 28 ⁸Genentech, South San Francisco, CA
- 29 ⁹Genes and Human Disease Research Program, Oklahoma Medical Research Foundation,
- 30 Oklahoma City, OK
- 31 ¹⁰Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-
- 32 Salem, NC
- ¹¹Center for Precision Medicine, Wake Forest School of Medicine, Winston-Salem, NC 33
- 34 ¹²Division of Genetics, Brigham and Women's Hospital, Boston, MA
- 35 ¹³Department of Biomedical Informatics, Harvard Medical School, Boston, MA
- ¹⁴Department of Genetics, Yale School of Medicine, New Haven, CT 36

37 Abstract:

38

Autoimmune and inflammatory diseases are polygenic disorders of the immune system. Many genomic loci harbor risk alleles for several diseases, but the limited resolution of genetic mapping

40 genomic loci harborrisk alleles for several diseases, but the limited resolution of genetic mapping 41 prevents determining if the same allele is responsible, indicating a shared underlying mechanism.

42 Using a collection of 129,058 cases and controls across six diseases, we show that ~40% of

43 overlapping associations are due to the same allele. We improve fine-mapping resolution for

44 shared alleles two-fold by combining cases and controls across diseases, allowing us to identify

45 more eQTLs driven by the shared alleles. The patterns of sharing indicate widespread shared

46 mechanisms, but not a single global autoimmune mechanism. Our approach can be applied to

47 any set of traits, and is particularly valuable as sample collections become depleted.

48 Main Text:

49

Autoimmune and inflammatory diseases are a heterogeneous group of disorders, where 50 51 activation of both the adaptive and innate immune system coupled with loss of self-tolerance 52 leads to target tissue destruction (1). These diseases are heritable, and genome-wide association 53 studies (GWAS) have identified hundreds of susceptibility loci, confirming their polygenic nature 54 (2, 3). Like other complex disease risk traits, heritability is strongly enriched in gene regulatory 55 regions active in specific cell populations (4-6), suggesting risk is mediated to a large extent by 56 altering gene expression in specific cell types under specific conditions. These diseases are also 57 comorbid (7, 8), with dual diagnoses being more frequent in individuals than expected by chance, 58 and multiple diseases aggregating in families (9). We and others have shown that many genetic 59 loci harbor risk variants for multiple autoimmune diseases (10-12), suggesting that comorbidity 60 may be due to shared genetic liability and, hence, shared mechanisms of disease.

61

62 Instances of pleiotropy, where the same variant influences risk to more than one disease, would 63 by definition point to a shared molecular effect, and thus a shared mechanism. The limited 64 resolution of genetic mapping has made it difficult to distinguish such cases from situations where distinct genetic variants in the same locus mediate risk to different diseases. This limited 65 66 resolution restricts our ability to uncover shared pathogenic mechanisms, understand why some 67 modulating immune functions can increase risk to one disease whilst decreasing risk to others, 68 or make inferences about the origins of these diseases and their different prevalence rates 69 around the world.

70

71 An important driver of the limited resolution of genetic mapping is disease cohort sample size 72 (13). Currently available disease cohorts, most of which have been extensively studied already, 73 are the result of decades-long international recruitment efforts. Meaningful increases in sample 74 size are thus difficult to envision in the immediate future. An alternative way to increase sample 75 size, and thus genetic mapping resolution, would be to jointly analyze cohorts across diseases. This would also reveal shared pathogenic mechanisms. In conventional meta-analyses of 76 77 cohorts with the same disease, we assume that any associations are shared across strata; we 78 cannot make this assumption across diseases. It is thus crucial to ensure that the same allele 79 drives risk to two or more diseases, rather than separate alleles in the same genomic locus.

80

81 Here, we first show substantial genome-wide shared heritability between autoimmune and 82 inflammatory diseases (Fig. S1). We then look at 224 instances where genetic associations to 83 multiple diseases occur in the same genomic region, and show that 41.5% of these observed 84 associations are due to pleiotropic variants, with the remainder being due to different alleles in 85 the region. When we combine cases and controls across diseases to map each shared association, we increase fine-mapping resolution two-fold on average. Further, this increase in 86 87 resolution reveals new disease risk variants that alter gene expression in immune cell subtypes. 88 Comorbidity is widespread between diseases of all organ systems, and sample sizes are limited, 89 so this strategy is widely applicable beyond the immune-mediated diseases. Thus, this approach 90 to careful dissection of shared effects can reveal mechanisms that are common across diseases 91 and pinpoint key genes driving shared biology.

92

We first assessed the evidence for genome-wide shared heritability between 19 autoimmune and inflammatory diseases from GWAS summary data. After quality control, we used LD score regression (14) to estimate heritability (h_g^2) for each trait (Fig. S2A). We found that 13/19 diseases had sufficient heritability captured by common variants to make these comparisons meaningful

97 (Z-score > 4) (15), so we restricted our analysis to this subset. We then calculated the proportion 98 of shared heritability between each pair of diseases, again using LD score regression, which is robust to sample overlaps between cohorts (15). We found a broad pattern of shared heritability 99 (Fig. 1), with the strongest overlaps (0.63 $\leq r_g \leq$ 0.92) between IBD and its subtypes, Crohn 100 disease and ulcerative colitis; these are known to share the majority, but not the entirety, of their 101 genetic architecture (16). We also observed strong correlations between atopic dermatitis, 102 103 asthma and allergic traits (0.51 $\leq r_g \leq$ 0.91), which may represent a shared basis for atopic inflammatory disease. We saw a strong correlation between systemic sclerosis and systemic 104 lupus erythematosus, which were also correlated with primary biliary cirrhosis ($0.42 \le r_q \le 0.86$). 105 In line with our previous findings (10, 17), these results indicate that autoimmune and 106 107 inflammatory diseases share a substantial portion of genetic risk factors, even when accounting 108 for the major histocompatibility locus (MHC), where overlapping haplotypes confer risk to different autoimmune and inflammatory diseases (18). Overall, this suggests that some 109 110 mechanisms are common between sets of diseases, but we find no evidence of universal sharing 111 indicative of a large core autoimmune susceptibility component (10, 17).



113 114 Fig. 1: Joint analysis of shared autoimmune disease risk alleles improves fine-mapping two-fold. (A) 115 We find broad genome-wide correlation between association statistics for susceptibility to thirteen 116 autoimmune and inflammatory diseases for which genome-wide association data were available (vitiligo, 117 Vit; atopic dermatitis, AtD; allergy, All; asthma, Ast; ulcerative colitis, UC; inflammatory bowel disease, 118 IBD; Crohn disease, CD; multiple sclerosis, MS; rheumatoid arthritis, RA; celiac disease, CeD; systemic 119 lupus erythematosus, SLE; primary biliary cirrhosis, PBC; and systemic sclerosis, SSc). (B) This correlation 120 is reflected in many loci harboring risk alleles to more than one of six diseases with available ImmunoChip 121 data (lower triangle). Of these 236 pairs of associations, 99 are driven by the same underlying allele (upper 122 triangle). (C) Risk alleles are mostly shared between two diseases (38 cases), with thirteen shared between 123 three, and six between four diseases. (D) Twelve shared alleles have opposite effect directions, increasing 124 risk of one disease and decreasing risk of another. This is most frequent between MS and IBD. (E) 125 Combining cases and controls across diseases increases fine-mapping resolution for these shared 126 associations. We assess resolution as the number of variants required to explain 95% of the posterior 127 probability of association. This credible interval decreases by 58% when combining samples across 128 diseases (red) compared to using only samples for one disease (orange). Associations that are not shared 129 across diseases have similar credible interval distributions in individual diseases (blue).

130

112

While this shared heritability gives an overall impression of the relationship between diseases, it 131 cannot identify specific genetic risk factors-and thus, genes and pathways-shared between 132 133 diseases. To compare samples from different collections genotyped at different centers, it was 134 important to minimize batch effects by ensuring all samples were profiled on the same platform. 135 We therefore chose six autoimmune and inflammatory diseases with large numbers of samples 136 genotyped on the ImmunoChip (19) (celiac disease, inflammatory bowel disease, multiple 137 sclerosis, rheumatoid arthritis, systemic lupus erythematosus and type 1 diabetes; Fig. S1). This 138 targeted array interrogates variants in 188 known risk loci to saturation, representing only 1.9% 139 of the genome but capturing 38-86% of risk loci that have been identified in the six diseases 140 (Fig. S3A). Using partitioned LD score regression, we confirmed that ImmunoChip regions 141 account for 27.6% (MS) to 46.3% (CeD) of the estimated heritability for five of the six diseases 142 for which GWAS data was available (Fig. S2B). After quality control, removal of population 143 outliers, resolution of duplicate and related samples, and imputation to the 1,000 Genomes 144 reference haplotypes, we analyzed a total of 104,302 SNPs in 188 non-MHC genomic regions 145 for association with disease in 82,630 cases and 104,573 controls (Fig. S1; see Supplementary 146 Text for additional details).

147

148 We first identified associations across the 188 loci in each disease independently by assembling 149 cases and controls into homogeneous population strata and meta-analyzing across these 150 groups. As multiple independent associations at a locus have been described in all diseases, we 151 used stepwise logistic regression followed by fixed-effects meta-analysis to allow for such 152 effects. We found 197 independent associations in 123 different ImmunoChip loci at genome-153 wide significance ($P < 5 \times 10^{-8}$), and 361 associations at 166 loci with suggestive association 154 evidence ($P < 10^{-5}$, Fig. S3B). Overall, we find some level of support for essentially all known genome-wide significant effects in the ImmunoChip regions. 155

156

157 We found substantial evidence for multiple independent associations within loci, with 7% (RA) 158 to 30% (IBD) of loci exhibiting more than one independent effect (Fig. S3C). This included three 159 instances of associations that have not been reported before (Fig. S4). In celiac disease, we 160 found suggestive unconditioned associations at two loci: a variant intronic to ANKS1A on 161 chromosome 6 (rs12206298; $P = 4.1 \times 10^{-7}$), and a variant intronic to CTSH on chromosome 15 (rs3784539; $P = 1.3 \times 10^{-5}$). After conditional association, both these associations passed the 162 genome-wide significance threshold ($P = 4.9 \times 10^{-8}$ and 1.1×10^{-8} respectively). We found 163 evidence of a second, independent effect in each locus (rs4713844, $P = 9.9 \times 10^{-8}$; and 164 165 rs7181033, $P = 8.7 \times 10^{-5}$). Similarly, in IBD, we found that a suggestive association in the 166 CLEC16A locus on chromosome 16 (rs7201325, $P = 1.4 \times 10^{-7}$) reached genome-wide significance after conditioning ($P = 1.1 \times 10^{-10}$), with evidence of a secondary, independent effect 167 168 (rs55773334, $P = 7.6 \times 10^{-5}$). The presence of multiple masked independent effects highlights 169 the need to look carefully at suggestive associations.

170

171 Having ensured we were capturing most of the known associations in ImmunoChip loci for each 172 of the six diseases, we looked for shared effects across diseases, i.e. whether the same variant mediates risk to more than one disease. We found 224 overlapping conditionally independent 173 associations at 98 loci (a lead variant associated to one disease at $P < 10^{-5}$, and a lead variant 174 for another disease $P < 10^{-4}$; both lead variants being in LD $r^2 > 0.5$ with at least one common 175 SNP). Using joint likelihood mapping (JLIM), we found evidence of a shared effect in 93/224 176 (41.5%) such overlaps, involving a total of 56 conditionally independent shared effects spanning 177 178 53 unique loci (Figure 1B). Of these, 40 effects were shared between two diseases, ten between 179 three, and six between four diseases (Fig. 1C). Unlike previous reports, which could not

distinguish between shared and distinct associations with multiple diseases in a locus, these
 observations indicate that many mechanisms are shared between autoimmune and inflammatory
 diseases.

183

184 We found three loci where multiple conditionally independent associations for one disease were 185 shared. In the STAT4 locus, we found two independent effects each for RA and SLE were shared 186 (Fig. S5A). In the CD28-CTLA4 locus, one T1D risk association near CD28 is shared with CeD, 187 whereas another, an intronic variant in CTLA4 is shared with RA (Fig. S5B). In the TYK2 locus, one RA risk association is shared with SLE, IBD, and T1D; a second association, localizing to 188 189 ICAM3, is shared with SLE alone (Fig. S5C). Cumulatively, these examples demonstrate that 190 disease-associated alleles in the same locus can have different consequences, and that careful 191 comparisons across diseases can distinguish each effect.

192

193 We next assessed if joint analysis across diseases could improve fine-mapping resolution. For 194 each of the 56 shared associations, we assembled conditionally independent association data 195 across all disease cohorts sharing that association, and combined them with fixed-effects. 196 inverse variance-weighted meta-analysis. In a subset of loci, we saw an unexpected decrease 197 in significance and increase in heterogeneity in the meta-analysis; we found these to be shared 198 associations with opposite effects, where an allele increases risk for one disease and decreases 199 it for the other (Fig. S6-S15). In six of these ten cases, variants with opposing effects were shared 200 between MS and IBD. After inverting the association statistics to account for these effects, our 201 meta-analysis resulted in higher significance for 123/134 (91.8%) associations across all 53 loci 202 harboring a shared effect, demonstrating the potential to bolster association findings with our 203 approach.

204

205 To establish if this increase in sample size provides a meaningful increase in fine-mapping 206 resolution, we used FINEMAP (20) to calculate posterior inclusion probabilities for SNPs at each 207 of the 56 shared effects, both in individual diseases and in the cross-disease meta-analysis. We 208 then calculated 95% credible sets for each disease, both before and after cross-disease meta-209 analysis. We found a substantial decrease in the mean credible interval size, from 37.2 (s.d. 46.4) 210 to 17.3 (s.d. 20.8), representing an improvement of 54% (Fig. 1E). We saw resolution 211 improvement across the spectrum of initial association evidence, with the largest gains where 212 an effect had relatively weak evidence of association in a disease: for associations below 213 genome-wide significance in a single disease, our resolution increased from a mean of 51.8 214 SNPs to 18.6 SNPs after cross-disease meta-analysis; for associations already above genome-215 wide significance in a single disease, we saw improvement from a mean of 21.7 SNPs to 15.9 216 SNPs. This is exemplified by a shared association in the *C1orf106* locus on chromosome 1, where credible intervals of 28, 8, and 11 SNPs for CeD, IBD and MS respectively are reduced to 217 eight variants in very tight linkage disequilibrium (minimum $r^2 = 0.976$) on cross-disease meta-218 219 analysis (Fig. 2). In this case, there are genome-wide significant associations in each disease 220 independently, but increasing sample size from symmetric equivalent 19,026 (CeD), 53,312 (IBD), 221 35,618 (MS) to a cross-disease meta-analysis 93,001 (symmetric equivalent) increases the 222 resolution for both CeD and MS, identifying a core risk haplotype within C1orf106.



224 225

Fig. 2: A shared effect on chromosome 1 can be fine-mapped to eight variants across celiac disease, 226 inflammatory bowel disease, and multiple sclerosis. (A) Overlapping associations in celiac disease, 227 inflammatory bowel disease and multiple sclerosis on chromosome 1, with 95% credible intervals varying 228 both in number of variants and physical span. (B) For each pair of diseases, the strength of association 229 (vertical axis) for the first trait decays in a linear fashion as a function of r^2 to the lead SNP in the second 230 trait, consistent with a shared causal variant. (C) Meta-analyzing across the three diseases gives in a 231 stronger association signal, which can be fine-mapped to a narrow interval within C1orf106. (D) We find 232 strong pairwise evidence that the association is shared between all three diseases; JLIM is asymmetric, 233 so we run comparisons in both directions.

234

235 The ultimate promise of increasing fine-mapping resolution is to increase the interpretability of 236 association signals. We and others have shown that disease risk associations are enriched in 237 non-coding regions with gene regulatory potential (4, 5, 21, 22). We have used the JLIM 238 approach to show that autoimmune disease associations are sometimes shared with expression 239 quantitative trait locus (eQTL) signals, indicating the risk allele also influences gene expression. 240 However, most associations are not shared with an eQTL, nor are they attributable to coding 241 variants. To assess if this is due to limitations in fine-mapping resolution, we looked for shared 242 associations between the 56 shared effects we discovered and cis-eQTLs for nearby genes in 243 naïve T cells, monocytes and neutrophils in the BLUEPRINT dataset. We found 137 shared 244 effects between each of 134 shared conditionally independent association signals in a single 245 disease and eQTLs for nearby genes. We then looked for shared effects between the better-246 powered cross-disease meta-analysis data in each of the 53 loci, and can attribute 21 new 247 disease/eQTL effects to the underlying diseases (Fig. 3; Table S3). Most of the implicated eQTLs

248 are present in only one of the three cell types we interrogated, with T cells providing the largest 249 number. We also exclude 11/137 disease/eQTL shared effects as no longer relevant because we 250 do not find evidence of shared association between the cross-disease meta-analysis and eQTL data. Our gains primarily occur in cases where the cross-disease meta-analysis reduces the 251 252 credible interval size (Fig. 3C), indicating that this gain of resolution drives these new 253 observations.

254

266

255 The direction of shared eQTL effects indicate whether we should expect increases or decreases 256 in expression for those genes to increase disease risk. We reasoned that we might also see the same direction of effect between cases and controls, where the risk state is magnified. We 257 258 therefore looked at single cell RNAseg data derived from T cells collected from a cohort of MS 259 patients and healthy controls (23). After guality control, we were able to detect twelve genes that 260 were targets of eQTLs shared with MS risk signals in our analysis. We found a significant pattern of correlation (P = 0.018): when a disease risk allele increased expression of a target gene, we 261 262 saw higher expression in cases than in controls, and when it decreased expression we saw lower 263 levels in cases than in controls (Fig. 3D). This suggests that shared associations do in fact drive 264 risk-altering changes to gene regulation alter disease risk, and our results are uncovering 265 pathogenic mechanisms.





Fig. 3: The increased resolution of fine-mapping shared associations across diseases allows 269 identification of more disease-eQTL overlaps. (A) We looked for shared effects between disease 270 associations and expression QTLs in loci harboring shared disease effects. When considering each 271 disease separately, we find 139 significant disease-eQTL overlaps across monocytes, neutrophils and T 272 cells from the BLUEPRINT consortium (left panel). When comparing eQTLs to cross-disease meta-273 analyses, we find new overlaps (blue, middle panel) and no longer find evidence for some eQTLs (red, 274 middle panel), for a grand total of 157 disease-eQTL overlaps (13% net discovery increase, right panel). 275 (B) Some of the shared eQTL effects can be detected in multiple tissues, but most are restricted to a single 276 cell type, indicating substantial effect specificity. (C) We find new eQTL shared effects in loci where the

cross-disease meta-analysis decreases the credible interval substantially, suggesting this resolution drives new discoveries. Disease associations where an eQTL is lost after meta-analysis also have smaller credible intervals, suggesting these may have been false positive findings due to lack of resolution in individual disease datasets. (D) The effects of risk-increasing shared alleles on gene expression is mirrored in expression differences between multiple sclerosis cases and controls. This suggests that risk states imparted due to small changes in gene expression persist during active disease, and provide validation that our eQTL discoveries are relevant to pathogenesis.

284

285 The relative direction of the disease and eQTL associations can also suggest specific 286 mechanistic hypotheses. This is exemplified by an association in the RGS1 locus, shared 287 between celiac disease and MS (Fig. 4). The cross-disease meta-analysis reduces the credible 288 interval to 10 variants overlapping the promoter region of RGS1, which encodes a regulator of 289 G-protein mediated signaling active in immune cell populations. We find a shared association 290 between disease risk and RGS1 expression in CD4 T cells, which is inverted so that lower 291 expression correlates with higher disease risk. The lead credible interval variant overlaps a region 292 of accessible chromatin within an active enhancer immediately upstream of the RGS1 promoter. 293 Further, this variant is annotated as a binding site for ZNF263 in the JASPAR database, and 294 position-weight matrix analysis suggests the minor allele abrogates this binding site (24).

295



296 297 Fig. 4: Jointly analyzing an association shared between multiple sclerosis and celiac disease 298 improves fine-mapping resolution and identifies a shared eQTL for RGS1. (A) Overlapping 299 associations for the two diseases are due to a shared effect (JLIM $P = 5 \times 10^{-5}$ for CeD as primary trait; P 300 $< 5 \times 10^{-5}$ for MS as primary trait). Meta-analyzing across the two diseases increases the overall 301 significance and a narrower credible interval (credible interval variants for each panel are in dark grey; the 302 physical span of the credible interval is shaded grey). The credible interval focuses on the intergenic region 303 proximal to RGS1. (B) This shared association is also shared with an eQTL for RGS1 in naïve CD4 T cells 304 (JLIM P = 0.015). (C) The lead disease-associated variant lies in a region of accessible chromatin in naïve 305 CD4 T cells and total T cells. This is marked with H3K27ac in total T cells and with H3K4me1 in naïve CD4 306 T cells, suggesting this is an active, primed enhancer element. (D) The RGS1 eQTL lead variant predicts 307 the disease association P value, further indicating this is a shared effect. (E) Disease and eQTL association 308 effects are negatively correlated, indicating that disease risk is associated with lower RGS1 expression.

309 (F) *RGS1* is expressed at lower levels in T cells obtained from MS patients compared to healthy controls,310 confirming this risk effect direction.

311

312 We have quantified the shared heritability between autoimmune and inflammatory diseases, and 313 demonstrated that we can leverage this to identify genetic variants that alter risk to multiple 314 diseases. This significantly increases fine-mapping resolution, compared to the original genetic 315 mapping studies: the number of effects where a single variant explains 95% of the posterior 316 probability of association increases from 13 to 20 (a 54% increase); for 50% of the posterior 317 probability, we see an increase from 35 to 54 (also 54%). Furthermore, we see an increase in the 318 number of eQTLs, with evidence of sharing an effect with disease risk, from 139 to 154 (11%). 319 Thus, in terms of identifying causal variants and functional interpretation, meta-analyzing across 320 diseases meaningfully increases our ability to interpret genetic associations. This sets the stage 321 for variant-to-function efforts to uncover key pathogenic mechanisms, as we provide high-value 322 targets relevant to multiple diseases.

323

324 This approach can be applied to any set of traits sharing associations; we therefore suggest this 325 is a fruitful avenue to maximize the interpretability of existing genetic studies of human complex 326 traits, especially as shared mechanisms are applicable to multiple conditions. It is particularly 327 valuable as sample collections, particularly of diseases that are difficult to diagnose or not 328 especially common in the population, become depleted. Disease cohorts are often genotyped 329 on different platforms, and the majority of common variants imputed. This can introduce a 330 substantial bias, if cohorts of samples with different diseases have differential genome coverage. 331 We have avoided this in our study by using a common platform, at the expense of not covering 332 the entire genome. These technical hurdles will diminish as genotyping platforms coalesce 333 around a standard set of variants, and as the community shifts to whole-genome sequencing 334 rather than genotyping. We note that biological interpretation of genetic associations, shared or otherwise. is dependent on access to molecular and cellular phenotype studies such as eQTLs, 335 336 which require profiling a wide array of tissues or cell types under diverse stimuli in order to 337 identify the consequences of disease-associated variants. The BLUEPRINT dataset, which we 338 used here, covers three very different blood cell types, but dozens more exist, in which the 339 variants we have identified could act. This context specificity may be one reason we cannot 340 always assign a cognate eQTL to each well-resolved association (25).

341

342 In terms of understanding the common mechanisms in autoimmunity, we and others have 343 reported that many loci harbor associations to multiple autoimmune diseases. However, these 344 approaches have relied on simple proximity of variants to infer that the underlying mechanisms 345 must be shared. We have, for the first time, quantified the shared heritability between 346 autoimmune and inflammatory diseases, and shown that a substantial proportion of shared loci 347 harbor pleiotropic effects influencing risk to multiple diseases, which represent shared 348 mechanisms. Many loci, however, harbor multiple independent effects, indicative of distinct 349 mechanisms driving risk to different diseases; this is consistent either with the same underlying 350 genes being influenced in different contexts to induce risk for different diseases, or with different 351 genes which happen to be encoded near each other. Previous studies by us and others were 352 not designed with this resolution, and could only identify loci harboring potentially different 353 effects to multiple diseases.

354

Our results reveal complex patterns of shared heritability between autoimmune diseases. In particular, we find many opposite effects shared between IBD and MS, where the same allele increases risk for one disease but decreases risk for the other. This is reminiscent of the

358 differential outcomes of anti-TNFa therapies, which are beneficial in IBD but exacerbate MS 359 symptoms (26). Further, it suggests that some disease mechanisms may have an optimum state, 360 and either hypermorphism or hypomorphism are deleterious. Overall, we see no evidence for a 361 substantial component of risk shared across all six diseases, which would be indicative of a pan-362 autoimmunity mechanism. Our benchmarking suggests this is not due to a lack of power to 363 detect shared effects (27), and our results strongly support independent effects in most loci. As 364 our results argue against a single, shared autoimmune mechanism, they also dispute a single evolutionary origin for autoimmune and inflammatory diseases, which would have resulted in a 365 366 set of risk alleles driving broad autoimmunity.

367 **References and Notes**

- 368
- M. D. Rosenblum, K. A. Remedios, A. K. Abbas, Mechanisms of human autoimmunity. *J. Clin. Invest.* **125**, 2228–2233 (2015).
- International Multiple Sclerosis Genetics Consortium, Multiple sclerosis genomic map
 implicates peripheral immune cells and microglia in susceptibility. *Science*. 365 (2019),
 doi:10.1126/science.aav7188.
- K. M. de Lange, L. Moutsianas, J. C. Lee, C. A. Lamb, Y. Luo, N. A. Kennedy, L. Jostins,
 D. L. Rice, J. Gutierrez-Achury, S.-G. Ji, G. Heap, E. R. Nimmo, C. Edwards, P.
- Henderson, C. Mowat, J. Sanderson, J. Satsangi, A. Simmons, D. C. Wilson, M.
- 377 Tremelling, A. Hart, C. G. Mathew, W. G. Newman, M. Parkes, C. W. Lees, H. Uhlig, C.
- Hawkey, N. J. Prescott, T. Ahmad, J. C. Mansfield, C. A. Anderson, J. C. Barrett,
 Genome-wide association study implicates immune activation of multiple integrin genes in
 inflammatory bowel disease. *Nat. Genet.* 49, 256–261 (2017).
- M. T. Maurano, R. Humbert, E. Rynes, R. E. Thurman, E. Haugen, H. Wang, A. P.
 Reynolds, R. Sandstrom, H. Qu, J. Brody, A. Shafer, F. Neri, K. Lee, T. Kutyavin, S.
 Stehling-Sun, A. K. Johnson, T. K. Canfield, E. Giste, M. Diegel, D. Bates, R. S. Hansen,
 S. Neph, P. J. Sabo, S. Heimfeld, A. Raubitschek, S. Ziegler, C. Cotsapas, N.
 Sotoodehnia, I. Glass, S. R. Sunyaev, R. Kaul, J. A. Stamatoyannopoulos, Systematic
 Localization of Common Disease-Associated Variation in Regulatory DNA. *Science*. 337, 1190–1195 (2012).
- A. Gusev, S. H. Lee, G. Trynka, H. Finucane, B. J. Vilhjálmsson, H. Xu, C. Zang, S. Ripke, B. Bulik-Sullivan, E. Stahl, SWE-SCZ Consortium, A. K. Kähler, C. M. Hultman, S. M.
 Purcell, M. Daly, B. Pasaniuc, P. F. Sullivan, B. M. Neale, N. R. Wray, S. Raychaudhuri, A.
 L. Price, Schizophrenia Working Group of the Psychiatric Genomics Consortium, S. A.
 McCarroll, Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases. *Am. J. Hum. Genet.* **95**, 535–552 (2014).
- H. K. Finucane, B. Bulik-Sullivan, A. Gusev, G. Trynka, Y. Reshef, P.-R. Loh, V. Anttila, H. Xu, C. Zang, K. Farh, S. Ripke, F. R. Day, ReproGen Consortium, Schizophrenia Working Group of the Psychiatric Genomics Consortium, RACI Consortium, S. Purcell, E. Stahl, S. Lindstrom, J. R. B. Perry, Y. Okada, S. Raychaudhuri, M. J. Daly, N. Patterson, B. M. Neale, A. L. Price, Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat. Genet.* 47, 1228–1235 (2015).
- 400 7. K. Hemminki, X. Li, K. Sundquist, J. Sundquist, Shared familial aggregation of 401 susceptibility to autoimmune diseases. *Arthritis Rheum.* **60**, 2845–2847 (2009).
- 402 8. W. W. Eaton, N. R. Rose, A. Kalaydjian, M. G. Pedersen, P. B. Mortensen, Epidemiology
 403 of autoimmune diseases in Denmark. *J. Autoimmun.* 29, 1–9 (2007).
- 404 9. C.-F. Kuo, M. J. Grainge, A. M. Valdes, L.-C. See, S.-F. Luo, K.-H. Yu, W. Zhang, M.
 405 Doherty, Familial Aggregation of Systemic Lupus Erythematosus and Coaggregation of
 406 Autoimmune Diseases in Affected Families. *JAMA Intern. Med.* **175**, 1518–1526 (2015).
- 407 10. C. Cotsapas, B. F. Voight, E. Rossin, K. Lage, B. M. Neale, C. Wallace, G. R. Abecasis, J.
 408 C. Barrett, T. Behrens, J. Cho, P. L. De Jager, J. T. Elder, R. R. Graham, P. Gregersen, L.
- Klareskog, K. A. Siminovitch, D. A. van Heel, C. Wijmenga, J. Worthington, J. A. Todd, D.
 A. Hafler, S. S. Rich, M. J. Daly, FOCiS Network of Consortia, Pervasive sharing of genetic
 effects in autoimmune disease. *PLoS Genet.* 7, e1002254 (2011).
- 412 11. D. Ellinghaus, L. Jostins, S. L. Spain, A. Cortes, J. Bethune, B. Han, Y. R. Park, S.
- 413 Raychaudhuri, J. G. Pouget, M. Hübenthal, T. Folseraas, Y. Wang, T. Esko, A. Metspalu,
- 414 H.-J. Westra, L. Franke, T. H. Pers, R. K. Weersma, V. Collij, M. D'Amato, J. Halfvarson, A.
- 415 B. Jensen, W. Lieb, F. Degenhardt, A. J. Forstner, A. Hofmann, International IBD Genetics

- Consortium (IIBDGC), International Genetics of Ankylosing Spondylitis Consortium (IGAS),
 International PSC Study Group (IPSCSG), Genetic Analysis of Psoriasis Consortium
- 418 (GAPC), Psoriasis Association Genetics Extension (PAGE), S. Schreiber, U. Mrowietz, B.
- D. Juran, K. N. Lazaridis, S. Brunak, A. M. Dale, R. C. Trembath, S. Weidinger, M.
- 420 Weichenthal, E. Ellinghaus, J. T. Elder, J. N. W. N. Barker, O. A. Andreassen, D. P.
- 421 McGovern, T. H. Karlsen, J. C. Barrett, M. Parkes, M. A. Brown, A. Franke, Analysis of five 422 chronic inflammatory diseases identifies 27 new associations and highlights disease-423 specific patterns at shared loci, *Nat. Genet.* **48**, 510–518 (2016).
- 12. M. Sirota, M. A. Schaub, S. Batzoglou, W. H. Robinson, A. J. Butte, Autoimmune disease classification by inverse association with SNP alleles. *PLoS Genet.* **5**, e1000792 (2009).
- 426 13. M. van de Bunt, A. Cortes, I. Consortium, M. A. Brown, A. P. Morris, M. I. McCarthy,
 427 Evaluating the Performance of Fine-Mapping Strategies at Common Variant GWAS Loci.
 428 *PLOS Genet.* **11**, e1005535 (2015).
- 429 14. B. K. Bulik-Sullivan, P.-R. Loh, H. K. Finucane, S. Ripke, J. Yang, Schizophrenia Working
 430 Group of the Psychiatric Genomics Consortium, N. Patterson, M. J. Daly, A. L. Price, B.
 431 M. Neale, LD Score regression distinguishes confounding from polygenicity in genome432 wide association studies. *Nat. Genet.* 47, 291–295 (2015).
- B. Bulik-Sullivan, H. K. Finucane, V. Anttila, A. Gusev, F. R. Day, P.-R. Loh, ReproGen Consortium, Psychiatric Genomics Consortium, Genetic Consortium for Anorexia Nervosa of the Wellcome Trust Case Control Consortium 3, L. Duncan, J. R. B. Perry, N.
 Patterson, E. B. Robinson, M. J. Daly, A. L. Price, B. M. Neale, An atlas of genetic correlations across human diseases and traits. *Nat. Genet.* 47, 1236–1241 (2015).
- 437 Contentions across numan diseases and traits. *Nat.* Genet. 47, 1230–1241 (2013).
 438 16. L. Jostins, S. Ripke, R. K. Weersma, R. H. Duerr, D. P. McGovern, K. Y. Hui, J. C. Lee, L.
 439 P. Schumm, Y. Sharma, C. A. Anderson, J. Essers, M. Mitrovic, K. Ning, I. Cleynen, E.
 440 Théâtre, S. L. Spain, S. Raychaudhuri, P. Goyette, Z. Wei, C. Abraham, J.-P. Achkar, T.
 441 Ahmad, L. Amininejad, A. N. Ananthakrishnan, V. Andersen, J. M. Andrews, L. Baidoo, T.
 442 Balachur, P. A. Barmaton, A. Bitton, C. Bauahar, S. Brand, C. Börning, A. Cohain, S.
- Balschun, P. A. Bampton, A. Bitton, G. Boucher, S. Brand, C. Büning, A. Cohain, S.
 Cichon, M. D'Amato, D. De Jong, K. L. Devaney, M. Dubinsky, C. Edwards, D. Ellinghaus,
- L. R. Ferguson, D. Franchimont, K. Fransen, R. Gearry, M. Georges, C. Gieger, J. Glas, T.
- 445 Haritunians, A. Hart, C. Hawkey, M. Hedl, X. Hu, T. H. Karlsen, L. Kupcinskas, S.
- 446 Kugathasan, A. Latiano, D. Laukens, I. C. Lawrance, C. W. Lees, E. Louis, G. Mahy, J.
- 447 Mansfield, A. R. Morgan, C. Mowat, W. Newman, O. Palmieri, C. Y. Ponsioen, U.
- Potocnik, N. J. Prescott, M. Regueiro, J. I. Rotter, R. K. Russell, J. D. Sanderson, M.
 Sans, J. Satsangi, S. Schreiber, L. A. Simms, J. Sventoraityte, S. R. Targan, K. D. Tay
- Sans, J. Satsangi, S. Schreiber, L. A. Simms, J. Sventoraityte, S. R. Targan, K. D. Taylor,
 M. Tremelling, H. W. Verspaget, M. de Vos, C. Wijmenga, D. C. Wilson, J. Winkelmann, R.
- 450 IN. Tremening, H. W. Verspager, M. de Vos, C. Wijmenga, D. C. Wilson, J. Winkerna 451 J. Xavier, S. Zeissig, B. Zhang, C. K. Zhang, H. Zhao, International IBD Genetics
- 451 J. Aavier, S. Zeissig, B. Zhang, C. K. Zhang, H. Zhao, International IBD Genetics 452 Consortium (IIBDGC), M. S. Silverberg, V. Annese, H. Hakonarson, S. R. Brant, G.
- 452 Consortium (iibbGC), M. S. Silverberg, V. Annese, H. Hakoharson, S. R. Brant, G. 453 Radford-Smith, C. G. Mathew, J. D. Rioux, E. E. Schadt, M. J. Daly, A. Franke, M. Parkes,
- 454 S. Vermeire, J. C. Barrett, J. H. Cho, Host-microbe interactions have shaped the genetic 455 architecture of inflammatory bowel disease. *Nature*. **491**, 119–124 (2012).
- 456 17. A. Zhernakova, S. Withoff, C. Wijmenga, Clinical implications of shared genetics and 457 pathogenesis in autoimmune diseases. *Nat. Rev. Endocrinol.* **9**, 646–659 (2013).
- 458 18. V. Matzaraki, V. Kumar, C. Wijmenga, A. Zhernakova, The MHC locus and genetic
 459 susceptibility to autoimmune and infectious diseases. *Genome Biol.* 18, 76 (2017).
- 460 19. A. Cortes, M. A. Brown, Promise and pitfalls of the Immunochip. *Arthritis Res. Ther.* 13, 101 (2011).
- 462 20. C. Benner, C. C. A. Spencer, A. S. Havulinna, V. Salomaa, S. Ripatti, M. Pirinen,
 463 FINEMAP: efficient variable selection using summary data from genome-wide association
 464 studies. *Bioinforma. Oxf. Engl.* 32, 1493–1501 (2016).

- K. K.-H. Farh, A. Marson, J. Zhu, M. Kleinewietfeld, W. J. Housley, S. Beik, N. Shoresh, H.
 Whitton, R. J. H. Ryan, A. A. Shishkin, M. Hatan, M. J. Carrasco-Alfonso, D. Mayer, C. J.
 Luckey, N. A. Patsopoulos, P. L. De Jager, V. K. Kuchroo, C. B. Epstein, M. J. Daly, D. A.
 Hafler, B. E. Bernstein, Genetic and epigenetic fine mapping of causal autoimmune
 disease variants. *Nature*. 518, 337–343 (2015).
- 470 22. G. Trynka, C. Sandor, B. Han, H. Xu, B. E. Stranger, X. S. Liu, S. Raychaudhuri, Chromatin
 471 marks identify critical cell types for fine mapping complex trait variants. *Nat. Genet.* 45,
 472 124–130 (2013).
- J. L. Pappalardo, L. Zhang, M. K. Pecsok, K. Perlman, C. Zografou, K. Raddassi, A.
 Abulaban, S. Krishnaswamy, J. Antel, D. van Dijk, D. A. Hafler, Transcriptomic and clonal
 characterization of T cells in the human central nervous system. *Sci. Immunol.* 5 (2020),
 doi:10.1126/sciimmunol.abb8786.
- 477 24. S. Kumar, G. Ambrosini, P. Bucher, SNP2TFBS a database of regulatory SNPs affecting
 478 predicted transcription factor binding site affinity. *Nucleic Acids Res.* 45, D139–D144
 479 (2017).
- 480 25. B. D. Umans, A. Battle, Y. Gilad, Where Are the Disease-Associated eQTLs? *Trends*481 *Genet. TIG.* 37, 109–124 (2021).
- 482 26. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia
 483 MS/MRI Analysis Group, TNF neutralization in MS: Results of a randomized, placebo484 controlled multicenter study. *Neurology*. 53, 457–457 (1999).
- S. Chun, A. Casparino, N. A. Patsopoulos, D. C. Croteau-Chonka, B. A. Raby, P. L. De
 Jager, S. R. Sunyaev, C. Cotsapas, Limited statistical evidence for shared genetic effects
 of eQTLs and autoimmune-disease-associated loci in three major immune-cell types. *Nat. Genet.* 49, 600–605 (2017).
- A. Rasmussen, S. Sevier, J. A. Kelly, S. B. Glenn, T. Aberle, C. M. Cooney, A. Grether, E. 489 28. 490 James, J. Ning, J. Tesiram, J. Morrisey, T. Powe, M. Drexel, W. Daniel, B. Namjou, J. O. 491 Ojwang, K. L. Nguyen, J. W. Cavett, J. L. Te, J. A. James, R. H. Scofield, K. Moser, G. S. 492 Gilkeson, D. L. Kamen, C. W. Carson, A. I. Quintero-del-Rio, M. del Carmen Ballesteros, 493 M. G. Punaro, D. R. Karp, D. J. Wallace, M. Weisman, J. T. Merrill, R. Rivera, M. A. Petri, 494 D. A. Albert, L. R. Espinoza, T. O. Utset, T. S. Shaver, E. Arthur, J.-M. Anaya, G. R. 495 Bruner, J. B. Harley, The lupus family registry and repository. *Rheumatol. Oxf. Engl.* 50, 496 47–59 (2011).
- C. D. Langefeld, H. C. Ainsworth, D. S. Cunninghame Graham, J. A. Kelly, M. E. Comeau, 497 29. 498 M. C. Marion, T. D. Howard, P. S. Ramos, J. A. Croker, D. L. Morris, J. K. Sandling, J. C. 499 Almlöf, E. M. Acevedo-Vásquez, G. S. Alarcón, A. M. Babini, V. Baca, A. A. Bengtsson, G. 500 A. Berbotto, M. Bijl, E. E. Brown, H. I. Brunner, M. H. Cardiel, L. Catoggio, R. Cervera, J. 501 M. Cucho-Venegas, S. R. Dahlqvist, S. D'Alfonso, B. M. Da Silva, I. de la Rúa Figueroa, A. 502 Doria, J. C. Edberg, E. Endreffy, J. A. Esquivel-Valerio, P. R. Fortin, B. I. Freedman, J. 503 Frostegård, M. A. García, I. G. de la Torre, G. S. Gilkeson, D. D. Gladman, I. Gunnarsson, 504 J. M. Guthridge, J. L. Huggins, J. A. James, C. G. M. Kallenberg, D. L. Kamen, D. R. Karp, 505 K. M. Kaufman, L. C. Kottyan, L. Kovács, H. Laustrup, B. R. Lauwerys, Q.-Z. Li, M. A. 506 Maradiaga-Ceceña, J. Martin, J. M. McCune, D. R. McWilliams, J. T. Merrill, P. Miranda, 507 J. F. Moctezuma, S. K. Nath, T. B. Niewold, L. Orozco, N. Ortego-Centeno, M. Petri, C. A. Pineau, B. A. Pons-Estel, J. Pope, P. Raj, R. Ramsey-Goldman, J. D. Reveille, L. P. 508 509 Russell, J. M. Sabio, C. A. Aguilar-Salinas, H. R. Scherbarth, R. Scorza, M. F. Seldin, C. 510 Sjöwall, E. Svenungsson, S. D. Thompson, S. M. A. Toloza, L. Truedsson, T. Tusié-Luna, C. Vasconcelos, L. M. Vilá, D. J. Wallace, M. H. Weisman, J. E. Wither, T. Bhangale, J. R. 511 512 Oksenberg, J. D. Rioux, P. K. Gregersen, A.-C. Syvänen, L. Rönnblom, L. A. Criswell, C. 513 O. Jacob, K. L. Sivils, B. P. Tsao, L. E. Schanberg, T. W. Behrens, E. D. Silverman, M. E.

Alarcón-Riquelme, R. P. Kimberly, J. B. Harley, E. K. Wakeland, R. R. Graham, P. M.
Gaffney, T. J. Vyse, Transancestral mapping and genetic load in systemic lupus
erythematosus. *Nat. Commun.* 8, 16021 (2017).

- 517
- 518

519 Acknowledgements:

520 We thank the EAGLE eczema consortium for providing GWAS summary statistics. This 521 research utilizes resources provided by the T1DGC, a collaborative clinical study sponsored by 522 the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute 523 of Allergy and Infectious Diseases, National Human Genome Research Institute, National 524 Institute of Child Health and Human Development, and JDRF and supported by U01 525 DK062418. We thank the RACI consortium for access to RA data and the International IBD 526 Genetics Consortium for access to IBD data. De-identified data were provided from a total of 527 4617 samples (2563 SLE cases and 2054 population controls) in the Lupus Family Registry and 528 Repository collection (28) at the Oklahoma Medical Research Foundation. The SLE Genentech 529 samples were originally genotyped and analyzed as part of a large SLEGEN Consortium 530 Immunochip study (29).

531

532 **Funding:** MRL is supported by a Career Transition Fellowship from the Consortium of MS

533 Centers and the National MS Society. CG received a research fellowship from the Deutsche

- 534 Forschungsgemeinschaft (DFG, German Research Foundation) for this project. She further
- received funding from the Hans und Klementia Langmatz-Stifung and the Hertie Network of
- Excellence in Clinical Neuroscience, not related to this study. CW was supported by an ERC
 Advanced grant (FP/2007- 2013/ERC grant 2012-322698), the NWO Spinoza prize grant (NWO
- 537 SPI 92-266), a grant from Stiftelsen K. G. Jebsen, and The Netherlands Organ-on-Chip
- 539 Initiative an NWO Gravitation project (024.003.001) funded by the Ministry of Education,
- 540 Culture and Science of the government of The Netherlands. SW was supported by The
- 541 Netherlands Organ-on-Chip Initiative, an NWO Gravitation project (024.003.001) funded by the
- 542 Ministry of Education, Culture and Science of the government of The Netherlands. I.H.J. is
- supported by a Rosalind Franklin Fellowship from the University of Groningen and an NWO
- 544 VIDI grant (no. 016.171.047). This work is in part supported by NIH/NIAID grant R01 AI122220 545 to CC.
- 546

547 Authors contributions:

- 548 MRL, NC, CG, and MM curated and analyzed data;
- 549 DvH, CW, SW, IHJ, LP, IMSGC, SSR, RRG, PMG, CDL, and DAH provided data;
- 550 MRL and CC wrote and edited the manuscript, with input from all co-authors;
- 551 SC and SRS designed and implemented analytical methods;
- 552 CC conceptualized and oversaw the project.
- 553 554
- 554 **Competing interests:** None of the authors have any competing interests.
- 555
- 556 **Data and materials availability:** Dataset availability is documented in Table S1. Analysis
- 557 source code is available from the Cotsapas lab GitHub page.